Question Bank › The knock on the company is going stale

The knock on the company is going stale

The knock on the company is going stale: this quarter's own facts cut against the standing doubt

Calls Tested
287
Answered YES
68
Hit Rate
23.7%
rare by design

Flywire Corporation (FLYW) — this company's answers

NO on the Q1 2022 call 2022-05-14 B+
The model's full reasoning — Q1 2022 call → NO我们根据要求,需要判断是否有一个明确的、公司特定的疑虑,并且本季度的实际运营证据是否明显反驳了该疑虑。 从电话会议中,我们看到分析师多次询问关于利润率、投资、增长可持续性等问题。但最明显的公司特定疑虑可能是关于公司何时能实现盈利或EBITDA转正,因为公司目前调整后EBITDA为正但很小,且Q2预计为负。管理层在回答中强调了长期投资和未来杠杆,但并没有用本季度的实际运营证据来反驳这个疑虑,而是更多依赖未来计划。 另一个可能的疑虑是增长是否可持续,但管理层用客户增加、收入增长等实际数据回应了。 但更具体地,分析师问到了利润率下降和投资回报,管理层回答是投资是长期的,并提到Q1的客户增加和收入增长。但疑虑是“亏损何时结束”或“投资是否过度”,管理层没有用本季度实际发生的具体事件来反驳,而是说未来会看到杠杆。 然而,有一个明显的疑虑是:公司是否能够持续增长并最终盈利?管理层在回答中提到了本季度的实际结果,如收入增长47%,客户增加130个,但这些都是增长证据,而不是盈利证据。疑虑是盈利问题,但本季度调整后EBITDA为正,但同比下滑,且Q2预计为负,所以实际上本季度的证据并没有反驳疑虑,反而可能支持疑虑(因为EBITDA下滑)。 另一个可能的疑虑是:公司是否过度依赖教育或旅行?但管理层提到了各垂直领域的增长。 再仔细看,分析师问到了“投资是否值得”,管理层用客户增加和收入增长来回应,但这些都是增长指标,不是盈利指标。疑虑是“何时盈利”,但本季度EBITDA下滑,所以证据没有反驳。 但也许疑虑是“增长是否可持续”,而本季度客户增加和收入增长反驳了这一点。但疑虑必须是公司特定的,且是长期存在的。从电话会议看,分析师多次问及利润率、投资回报,这暗示了市场担心公司烧钱。但管理层没有用本季度的实际运营证据来反驳,而是说未来会看到杠杆。 然而,有一个点:管理层提到“我们提高了全年指引”,这可能是对疑虑的回应,但那是基于未来预期,不是本季度实际。 再考虑:是否有分析师直接问“你们何时盈利”?没有直接问,但问到了利润率。管理层回答时提到了本季度的实际结果,如“Q1调整后EBITDA为180万美元”,但同比下滑,所以没有反驳。 也许疑虑是“增长是否依赖疫情恢复”,但管理层用旅行数据反驳了。 我认为最明显的公司特定疑虑是:公司是否能够实现盈利,因为目前EBITDA很小且波动。但本季度的证据是EBITDA同比下滑,所以没有反驳。 另一个疑虑可能是“客户获取成本高”,但管理层用客户增加反驳了。 但根据要求,疑虑必须是在电话会议中可见的,且本季度实际证据反驳它。我注意到分析师问到了“投资是否值得”,管理层用“Q1 ARR签单和管道增长”来回应,但那是实际发生的。所以也许疑虑是“投资是否有效”,而本季度客户增加和收入增长反驳了。 但疑虑是“公司是否过度投资导致亏损”,而本季度收入增长47%,客户增加,但EBITDA下滑,所以证据是混合的。 也许疑虑是“增长是否可持续”,而本季度客户增加和管道增长反驳了。 但更具体地,我注意到管理层在回答中多次提到“长期投资”,分析师问“何时看到杠杆”,管理层说“未来会看到”,这没有用本季度实际反驳。 然而,有一个点:管理层提到“我们提高了全年指引”,这可能是对疑虑的回应,但那是基于未来预期,不是本季度实际。 再考虑:是否有分析师问“你们是否依赖单一市场”?没有。 我认为最符合的是:市场担心公司无法盈利,但本季度收入增长强劲,但EBITDA下滑,所以没有反驳。 也许疑虑是“增长是否放缓”,但本季度增长47%,反驳了。 但疑虑必须是公司特定的,且长期存在。从电话会议看,分析师反复问利润率,这暗示了市场担心利润率压力。管理层回答时提到了本季度的支付方式组合,但那是解释,不是反驳。 实际上,管理层说“Q1净利差与过去两年平均一致”,这反驳了利润率恶化的疑虑。但那是本季度的实际数据。 所以,疑虑可能是“利润率是否可持续”,而本季度净利差与历史一致,反驳了。 但那是关于利润率,不是盈利。 我认为更明确的疑虑是:公司是否能够实现盈利,因为目前EBITDA很小。但本季度EBITDA同比下滑,所以没有反驳。 也许疑虑是“增长是否依赖疫情恢复”,但旅行数据反驳了。 我决定选择NO,因为没有明确的公司特定疑虑被本季度实际证据反驳。管理层主要用未来计划回应,而不是本季度实际。 但再读一遍,分析师问“投资是否值得”,管理层说“Q1 ARR签单和管道增长”,这是实际发生的,反驳了投资无效的疑虑。所以也许有。 但疑虑是“投资是否过度”,而本季度客户增加反驳了。 我认为可以选YES,但需要确认。 根据要求,疑虑必须是在电话会议中可见的,且本季度实际证据反驳它。我注意到分析师多次问及利润率,管理层用本季度的支付方式组合和净利差回应,但那是解释,不是反驳。 也许疑虑是“增长是否可持续”,而本季度客户增加和管道增长反驳了。 但那是增长,不是盈利。 我倾向于NO,因为没有明显的公司特定疑虑被本季度实际证据反驳。管理层主要用未来计划回应。 但再考虑:分析师问“你们何时盈利”,没有直接问,但问到了利润率。管理层说“我们提高了全年指引”,那是未来。 我认为没有。 所以答案NO。

← Back to the full FLYW analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: Reading this call as a whole, can you identify ONE well-defined DOUBT that has clearly been weighing on how this company is perceived — a standing knock evident from the transcript itself, such as skepticism that its losses will ever end, that its main product or model will find repeat demand, that its legacy business's decline will swamp everything else, that it depends too heavily on one customer, market, or financing source, or another comparable company-specific concern — AND does the CURRENT PERIOD'S OWN OPERATING EVIDENCE, as recounted by management, move clearly AGAINST that doubt? Answer YES when BOTH halves come through in the transcript, in whatever form fits the business: (1) A STANDING, COMPANY-SPECIFIC DOUBT IS VISIBLE ON THE CALL. The transcript itself shows that a particular concern has hung over this company — through analysts returning to it, management acknowledging what skeptics or investors have worried about, or management plainly addressing a question it knows the audience carries (can this business make money, will anyone buy this at scale, will the decline stop, can they fund themselves, will the big customer stay). The doubt must be specific to this company's situation, not generic macro gloom, and must read as something that predates this quarter rather than arising on this call. (2) THIS PERIOD'S REAL ACTIVITY CUTS AGAINST IT. Management recounts concrete things that actually happened in the recent period — actual orders, customers returning or expanding, real revenue or volumes where there had been little, losses narrowing because of how the business itself is now running, the doubted product performing in real use, the feared departure or decline not occurring while something better did — described with enough operating substance that the contradiction rests on observed events rather than on reassurance, plans, or projections. The evidence need not fully settle the doubt; what matters is that the current period's facts point the other way and management engages the doubt with those facts. Answer NO if no company-specific doubt is discernible — an ordinarily healthy company reporting a routine quarter. NO if the doubt exists but management answers it mainly with confidence, vision, targets, or hoped-for improvements rather than with things that already happened. NO if the period's evidence actually confirms the doubt (the losses widened, the decline continued, the customer left) and management is excusing it. NO if the contrary evidence is a one-time item, an asset sale, a financing, or something management itself treats as non-recurring rather than the business operating differently. NO if the doubt and the evidence never connect — strong facts reported on one topic while the standing concern sits elsewhere untouched. NO if the doubt appears only as boilerplate risk language or an analyst aside that management never engages. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
CRGO Freightos Limited Q1 2024 2024-05-20 C+
IFS Intercorp Financial Services Inc. Q1 2024 2024-05-14 C+
PRA ProAssurance Corporation Q1 2024 2024-05-11 D
LTRX Lantronix, Inc. Q3 2024 2024-04-29 C
ASB Associated Banc-Corp Q1 2024 2024-04-25 A
GL Globe Life Inc. Q1 2024 2024-04-23 F
ASM Avino Silver & Gold Mines Ltd. Q4 2023 2024-03-21 C+
KOPN Kopin Corporation Q4 2023 2024-03-14 C+
GIII G-III Apparel Group, Ltd. Q4 2024 2024-03-14 C
HP Helmerich & Payne, Inc. Q1 2024 2024-01-30 C
PFE Pfizer Inc. Q4 2023 2024-01-30 F
QTRX Quanterix Corporation Q3 2023 2023-11-07 B
ALL The Allstate Corporation Q3 2023 2023-11-02 C+
DASH DoorDash, Inc. Q3 2023 2023-11-01 C+
PTN Palatin Technologies, Inc. Q4 2023 2023-09-29 D
BZUN Baozun Inc. Q2 2023 2023-08-28 D
GVP GSE Systems, Inc. Q1 2023 2023-05-15 D
BXSL Blackstone Secured Lending Fund Q1 2023 2023-05-10 A
FTHM Fathom Holdings, Inc. Q1 2023 2023-05-10 C
SPIR Spire Global, Inc. Q1 2023 2023-05-10 B
SBRA Sabra Health Care REIT, Inc. Q1 2023 2023-05-04 B
BRX Brixmor Property Group Inc. Q1 2023 2023-05-02 A
TACT TransAct Technologies Incorporated Q4 2022 2023-03-08 A
VRE Veris Residential, Inc. Q4 2022 2023-02-22 D
TOST Toast, Inc. Q4 2022 2023-02-16 C+
PKOH Park-Ohio Holdings Corp. Q3 2022 2022-11-13 B
CLSD Clearside Biomedical, Inc. Q3 2022 2022-11-09 C
SIBN SI-BONE, Inc. Q3 2022 2022-11-07 C+
CHE Chemed Corporation Q3 2022 2022-11-01 B+
YMM Full Truck Alliance Co. Ltd. Q2 2022 2022-08-25 C+
EXFY Expensify, Inc. Q2 2022 2022-08-12 D
WD Walker & Dunlop, Inc. Q2 2022 2022-08-09 C+
DM Desktop Metal, Inc. Q2 2022 2022-08-08 F
XHR Xenia Hotels & Resorts, Inc. Q2 2022 2022-08-05 A
LIN Linde plc Q2 2022 2022-07-28 B+
CME CME Group Inc. Q2 2022 2022-07-27 B
OGI OrganiGram Holdings Inc. Q3 2022 2022-07-14 B+
SE Sea Limited Q1 2022 2022-05-17 F
VNRX VolitionRx Limited Q1 2022 2022-05-12 F
OPK OPKO Health, Inc. Q1 2022 2022-05-09 D
FARM Farmer Bros. Co. Q3 2022 2022-05-07 D
BFIN BankFinancial Corporation Q1 2022 2022-05-06 A
BXP Boston Properties, Inc. Q1 2022 2022-05-03 A
STC Stewart Information Services Corporation Q1 2022 2022-04-29 C+
LOW Lowe's Companies, Inc. Q3 2021 2021-11-17 B+
CYBR CyberArk Software Ltd. Q3 2021 2021-11-04 B+
IPGP IPG Photonics Corporation Q3 2021 2021-11-02 C
SXC SunCoke Energy, Inc. Q3 2021 2021-11-01 A
EMR Emerson Electric Co. Q3 2021 2021-08-04 B+
EEX Emerald Holding, Inc. Q2 2021 2021-08-01 C+
GECC Great Elm Capital Corporation Q3 2018 2018-11-13 B
UMH UMH Properties, Inc. Q3 2018 2018-11-02 C+
FOSL Fossil Group, Inc. Q1 2018 2018-05-08 C
BCOV Brightcove Inc. Q1 2018 2018-04-26 B+
AVT Avnet, Inc. Q2 2018 2018-01-25 B
PII Polaris Inc. Q3 2017 2017-10-24 C+
GNTX Gentex Corporation Q3 2017 2017-10-20 B
MTG MGIC Investment Corporation Q3 2017 2017-10-18 B+
LIND Lindblad Expeditions Holdings, Inc. Q2 2017 2017-08-06 C
BIIB Biogen Inc. Q2 2017 2017-07-25 B
CAG Conagra Brands, Inc. Q2 2017 2016-12-22 C+
WYY WidePoint Corporation Q3 2016 2016-11-09 D
ULBI Ultralife Corporation Q3 2016 2016-10-29 C+
ARAY Accuray Incorporated Q4 2016 2016-08-17 B
GES Guess?, Inc. Q1 2017 2016-05-25 F
RCL Royal Caribbean Cruises Ltd. Q1 2016 2016-04-29 C+
DD DuPont de Nemours, Inc. Q1 2016 2016-04-26 B+
HPP Hudson Pacific Properties, Inc. Q4 2015 2016-02-25 C

How the model reasoned

BRX · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible on the call, and if this period's operating evidence cuts against it. YES The standing doubt is the skepticism that tenant disruptions (especially bankruptcies like Bed Bath) will create occupancy pressure and throw markets out of equilibrium, given the recaptured space and potential for more filings. This is visible in analyst questions (Todd Thomas on Bed Bath impact and market equilibrium; others circling back on bad debt 75-110 bps and bankruptcy activity) and management's acknowledgment that "recent retailer bankruptcy announcements will result in occupancy pressure" while noting they've "been preparing for the last several quarters." This period's evidence cuts against it: record 94% total occupancy (up sequentially in a seasonally weak quarter), small-shop at 89.
CME · Q2 2022 → YESThe question is: Identify ONE well-defined DOUBT that has been weighing on the company, and see if the current period's operating evidence moves against that doubt. YES The standing doubt is the perceived risk that the legacy NEX Group businesses (BrokerTec and EBS) would continue to show range-bound revenue and fail to deliver meaningful growth despite a constructive macro backdrop, as directly raised by Alex Blostein. Management engages this concern head-on by recounting concrete operating evidence from 2Q: BrokerTec US treasuries ADV up 14% YoY, US repo up 25% YoY, EU repo up 14% YoY, plus $4.5 billion in new cross-sell volume from previously non-trading clients and record RV trading volumes of $2.4 billion; 90% of the migration to Globex is complete, with the remaining EBS migration also finished and system enhancements underway.
BXSL · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible in the transcript, and if this period's operating evidence moves against it. YES The standing doubt visible in the transcript is the skepticism that BXSL’s credit performance will be materially worse than the broader private-credit market because of its exposure to higher-rate environments and the “tails” of the portfolio (i.e., the small slice of companies whose interest-coverage ratios could fall below 1× when 5 % rates are stress-tested). Management itself flags this concern by noting that “it is less about averages… much more about the tails” and that investors keep asking about the percentage of the portfolio below 1× ICR. This quarter’s operating evidence directly counters that doubt: - 0.

More from the question bank

Acted like it's already biggerBetting on a claim they haven't proven yetMoney already collected for work not yet donNew faces on the callThe streak is aliveCommitted past the numbersAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.